A greater percentage of moderate to severe chronic plaque psoriasis patients treated with briakinumab, Abbott's investigational IL-12/23 inhibitor, achieved 75% or better skin clearance rates than those treated with etanercept, methotrexate, or placebo.
Merck KGaA has notified the European Medicines Agency of its intention to request a re-examination of the opinion issued by the Committee for Medicinal Products for Human Use regarding Cladribine Tablets for relapsing-remitting multiple sclerosis.
The Supreme Court won't reconsider a decision to reinstate more than 100 lawsuits filed by women who claimed that hormone replacement therapy caused breast cancer.
Use of folic acid supplements appears to lower blood levels of the amino acid homocysteine—theorized to be a risk factor for heart and blood vessel disease—but does not appear to be associated with reduced rates of cardiovascular events, cancer or death.
When her stroke hit, Edna Wooten somehow stopped her car. Then her grown daughter ignored her slurred protests and raced her to the hospital - in time for a drug to dissolve the blood clot causing her stroke.
Geron Corp. has begun testing an embryonic stem-cell treatment on a patient with spinal cord injuries, marking the first time such a drug has been used on a human.
Parents who say their daughter allegedly suffered serious health problems from a childhood vaccine are trying to persuade the Supreme Court to allow them to sue the manufacturer.
Pfizer Inc., the world's largest pharmaceutical company by revenue, said it will buy pain drug maker King Pharmaceuticals Inc. for $3.6 billion in cash.
Keyence Corp.’s VHX-1000 digital microscope successfully integrates many of the optical properties and functionalities of stereoscopes, measuring microscopes, and scanning electron microscopes into an all-in-one.
JEOL USA, Inc. and the Japanese AIST have developed the ClairScope, a tool that couples optical microscopy with an atmospheric scanning electron microscope in an open culture system that retains the samples’ native state while under study.
VivaTome, an optical microscope accessory from Carl Zeiss and Aurox Ltd., addresses the problem of unwanted blurred information being included with the primary in-focus information from.
This month, I am pleased to share with you some features that are in our magazine, and some that are not. Editors are frequently frustrated by the physical limitations of the printed page.
In late September, the U.S. Food and Drug Administration issued a final rule that clarifies what safety information must be reported during clinical trials of investigational drugs and biologics.
Many articles describe assays that work in multi-well plates, but without the technology to read the results these assays are of limited benefit to the drug discovery and development process.